Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Sutro Biopharma (NASDAQ: STRO), a clinical-stage oncology company specializing in site-specific and novel-format antibody-drug conjugates (ADCs), has announced an inducement grant under Nasdaq Listing Rule 5635(c)(4). On September 16, 2024, the Compensation Committee of Sutro's Board of Directors granted 60,000 restricted stock units (RSUs) of Sutro common stock to a new employee.
The grant was made as an inducement for the employee's acceptance of employment with Sutro. The RSUs are subject to the terms of Sutro's 2021 Equity Inducement Plan. Vesting will occur over four years, with one-fourth of the shares vesting on the one-year anniversary of the employee's hire date and annually thereafter, contingent on the employee's continued service with Sutro.
Sutro Biopharma (NASDAQ: STRO), un'azienda oncolgica in fase clinica specializzata in coniugati di farmaci anticorpali a formato novità e specifici per il sito, ha annunciato un'incentivazione ai sensi della Regola di quotazione Nasdaq 5635(c)(4). Il 16 settembre 2024, il Comitato per la retribuzione del Consiglio di amministrazione di Sutro ha concesso 60.000 unità di azioni soggette a restrizioni (RSU) delle azioni ordinarie di Sutro a un nuovo dipendente.
La concessione è stata fatta come incentivo per l'accettazione dell'impiego presso Sutro. Le RSU sono soggette ai termini del Piano di incentivazione azionaria 2021 di Sutro. Il diritto di acquisire le azioni avverrà in quattro anni, con un quarto delle azioni che diventerà di proprietà al primo anniversario della data di assunzione del dipendente e annualmente in seguito, a condizione che il dipendente continui a lavorare per Sutro.
Sutro Biopharma (NASDAQ: STRO), una empresa de oncología en etapa clínica especializada en conjugados de anticuerpos y fármacos de formato novedoso y específicos para el sitio, ha anunciado un otorgamiento de incentivos bajo la Regla de Cotización 5635(c)(4) de Nasdaq. El 16 de septiembre de 2024, el Comité de Compensación de la Junta Directiva de Sutro otorgó 60,000 unidades de acciones restringidas (RSUs) de acciones ordinarias de Sutro a un nuevo empleado.
La concesión se realizó como un incentivo para la aceptación del empleo en Sutro. Las RSUs están sujetas a los términos del Plan de Incentivos de Capital de Sutro de 2021. La adquisición de derechos ocurrirá en un período de cuatro años, con una cuarta parte de las acciones adquiriendo derechos en el primer aniversario de la fecha de contratación del empleado y anualmente después, condicionada a la continuidad del servicio del empleado con Sutro.
수트로 바이오파마(Sutro Biopharma) (NASDAQ: STRO), 특정 부위와 새로운 형식의 항체-약물 접합체(ADCs)를 전문으로 하는 임상 단계의 종양학 회사가 나스닥 상장 규칙 5635(c)(4) 하에 유인 보조금(inducement grant)을 발표했습니다. 2024년 9월 16일, 수트로의 보상위원회는 새로운 직원에게 60,000개의 제한 주식 단위(RSUs)를 수트로의 보통주로 부여했습니다.
이 보조금은 직원의 수트로 채용 수락을 위한 유인이었습니다. RSU는 수트로의 2021년 주식 유인 계획의 조건에 따릅니다. 주식은 4년 동안 분할될 예정입니다, 직원의 채용일 1주년 기념일에 1/4이 부여되고 이후 매년 부여되며, 이는 직원의 지속적인 서비스에 따라 달라집니다.
Sutro Biopharma (NASDAQ: STRO), une société d'oncologie en phase clinique spécialisée dans les conjugués anticorporels-médicaments (ADCs) spécifiques à un site et à un format novateur, a annoncé une attribution d'incitation en vertu de la règle d'inscription Nasdaq 5635(c)(4). Le 16 septembre 2024, le Comité de rémunération du Conseil d'administration de Sutro a accordé 60 000 unités d'actions restreintes (RSUs) d'actions ordinaires de Sutro à un nouvel employé.
L'attribution a été faite comme incitation à l'acceptation de l'emploi chez Sutro. Les RSUs sont soumises aux termes du plan d'incitation en actions 2021 de Sutro. L'acquisition des droits se fera sur une période de quatre ans, avec un quart des actions acquérant des droits au premier anniversaire de la date d'embauche de l'employé et annuellement par la suite, conditionnée à la continuité du service de l'employé avec Sutro.
Sutro Biopharma (NASDAQ: STRO), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das sich auf standortspezifische und neuartige Antikörper-Wirkstoff-Konjugate (ADCs) spezialisiert hat, hat einen Anreizgewährung gemäß der Nasdaq-Listing-Regel 5635(c)(4) angekündigt. Am 16. September 2024 gewährte der Vergütungsausschuss des Vorstands von Sutro 60.000 beschränkte Aktieneinheiten (RSUs) an einen neuen Mitarbeiter.
Die Gewährung erfolgte als Anreiz für die Annahme der Anstellung bei Sutro. Die RSUs unterliegen den Bedingungen des Sutro Equity Inducement Plans von 2021. Die Vesting erfolgt über einen Zeitraum von vier Jahren, wobei ein Viertel der Aktien am ersten Jahrestag des Einstellungstags des Mitarbeiters und danach jährlich erdient wird, vorausgesetzt, der Mitarbeiter bleibt weiterhin bei Sutro beschäftigt.
- Sutro Biopharma is attracting new talent with equity incentives
- The company is complying with Nasdaq listing rules for inducement grants
- None.
SOUTH SAN FRANCISCO, Calif., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody-drug conjugates (ADCs), today announced that on September 16, 2024, the Compensation Committee of Sutro’s Board of Directors granted 60,000 restricted stock units (RSUs) of Sutro common stock to a new employee. The grant was made as an inducement material to the employee’s acceptance of employment with Sutro and was approved by the Compensation Committee of Sutro’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSUs are subject to the terms and conditions of Sutro’s 2021 Equity Inducement Plan. One-fourth of the total number of shares subject to the RSUs will vest on the one-year anniversary of the employee’s hire date and annually thereafter until fully vested on the fourth anniversary, subject to the employee’s continued service with Sutro on each such vesting date.
About Sutro Biopharma
Sutro Biopharma, Inc., is a clinical-stage company relentlessly focused on the discovery and development of precisely designed cancer therapeutics, to transform what science can do for patients. Sutro’s fit-for-purpose technology, including cell-free XpressCF®, provides the opportunity for broader patient benefit and an improved patient experience. Sutro has multiple clinical stage candidates, including luveltamab tazevibulin, or luvelta, a registrational-stage folate receptor alpha (FolRα)-targeting ADC in clinical studies. A robust pipeline, coupled with high-value collaborations and industry partnerships, validates Sutro’s continuous product innovation. Sutro is headquartered in South San Francisco. For more information, follow Sutro on social media @Sutrobio, or visit www.sutrobio.com.
FAQ
How many restricted stock units (RSUs) did Sutro Biopharma (STRO) grant to the new employee?
What is the vesting schedule for the RSUs granted by Sutro Biopharma (STRO)?
Under which Nasdaq rule did Sutro Biopharma (STRO) make the inducement grant?
What is Sutro Biopharma's (STRO) primary focus as a company?
